Eli Lilly Acquires AtaiBeckley for $2.8 Billion to Expand Neuroscience Portfolio
Eli Lilly recently announced its acquisition of clinical-stage biotech company AtaiBeckley for approximately $2.8 billion in cash, excluding potential milestone payments. This move is part of a broader strategy by Eli Lilly to expand and diversify beyond its successful GLP-1 drugs like Zepbound into the neuroscience space. AtaiBeckley's lead candidate, BPL-003, targets treatment-resistant depression with promising phase 2 results. The acquisition complements recent purchases such as Centessa Pharmaceuticals for $6.3 billion and strengthens Eli Lilly’s portfolio in mental health and neurological disorders. The company also has Alzheimer’s drug Kisunla under development, which is expected to reach peak sales of over $1 billion. Eli Lilly's aggressive expansion into neuroscience and other therapeutic areas like pain management, oncology, immunology, and infectious diseases aims to mitigate future competition in its core weight loss and diabetes markets. This strategy provides the company with multiple growth opportunities across diverse fields.
